GLP-1 Agonists can reduce risk of mortality, liver failure in patients with type 2 diabetes and cirrhosis
Taiwan: A recent population-based cohort study published in Clinical Gastroenterology and Hepatology has revealed multiple benefits of glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients with type 2 diabetes and compensated liver cirrhosis.
The study showed a lower risk of cardiovascular disease, death, liver failure, hepatic encephalopathy, and decompensated cirrhosis in the users of GLP-1 receptor agonists. However, the researchers add that there is a need for additional studies to confirm their results.
Liver cirrhosis is often associated with type 2 diabetes, but research is scarce on type 2 diabetes (T2D) treatment in cirrhosis patients. To fill this knowledge gap, Chii-Min Hwu, National Yang-Ming Chiao Tung University, Taipei, Taiwan, and colleagues sought to investigate the long-term outcomes of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cirrhosis.
For this purpose, the researchers selected 467 matched pairs of GLP-1 RA users and nonusers with T2D and compensated liver cirrhosis from the National Health Insurance Research Database of Taiwan using propensity-score matching from 2008 to 2019. Cardiovascular events, all-cause mortality, decompensated cirrhosis, and other key outcomes were compared between the two groups using multivariable-adjusted Cox proportional hazards models. The mean follow-up time was 3.06 years and 3.28 for GLP-1 RA nonusers and users, respectively.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.